Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study
Authors:
- Rahul R. AggarwalRARahul R. Aggarwal
- Antoine ItalianoAntoine Italiano
- Susan M. DomchekSDSusan M. Domchek
- Oscar GoodmanOGOscar Goodman
- Sophie Postel-VinaySPSophie Postel-Vinay
- Jesus García-DonásJGJesus García-Donás
- Tanya DorffTDTanya Dorff
- Zachery R. ReichertZRZachery R. Reichert
- Armelle VinceneuxAVArmelle Vinceneux
- Neal ShoreNSNeal Shore
- Catherine H. MarshallCMCatherine H. Marshall
- Joshua ArmeniaJAJoshua Armenia
Open Access
- 29 May 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Cancer Research Communications
- Vol. 6 (7) , 1546-1556
Abstract
Purpose: Ceralasertib is an oral ataxia telangiectasia and Rad3-related (ATR) inhibitor with preclinical activity in ataxia-telangiectasia mutated (ATM)-altered cancers. The phase 2a PLANETTE study evaluated ceralasertib in previously treated advanced solid tumors (Cohort A) or metastatic castration-resistant prostate cancer (Cohort B) with ATM alterations (ATM mutations and/or ATM protein deficiency). Patients and Methods: Patients received ceralasertib 160 mg BID on days 1–14 of a 28-day cycle. Efficacy was evaluated in patients with centrally confirmed ATM alterations. The primary endpoint was objective response rate (ORR; Cohort A) or composite response rate (CRR: radiographic response, PSA response, or circulating tumor cell conversion; Cohort B). Secondary endpoints included progression-free survival (PFS) and safety. Results: Cohorts A and B included 30 and 15 patients, respectively. ORR (Cohort A) was 7.1% (80% confidence interval [CI]: 1.9–17.9; n=2/28): one complete response ongoing at 14.1 months (breast cancer) and one partial response ongoing at 7.4 months (endometrial cancer). CRR (Cohort B) was 7.7% (80% CI: 0.8–28.6; n=1/13). In patients with centrally confirmed ATM protein loss, ORR was 18.2% (80% CI: 4.9–41.5; n=2/11) and CRR was 0% (80% CI: 0–28.0; n=0/7). Median PFS was 3.7 months in each cohort (Cohort A, 80% CI: 1.9–5.6; Cohort B, 80% CI: 1.9–not calculable). Grade ≥3 AEs occurred in 50.0% of Cohort A and 53.3% of Cohort B patients. The most common AEs overall were asthenia/fatigue, nausea, and anemia. Conclusions: Ceralasertib monotherapy was tolerated; however, responses were limited. Alternative patient selection and combination treatments are being explored.Keywords
This publication has 32 references indexed in Scilit:
- Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cellsOncogene, 2020
- A consensus set of genetic vulnerabilities to ATR inhibitionOpen Biology, 2019
- Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract CancerCancer Research and Treatment, 2019
- Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we standJournal of Hematology & Oncology, 2019
- Genome-wide CRISPR screens reveal synthetic lethality of RNASEH2 deficiency and ATR inhibitionOncogene, 2018
- Targeting the replication stress response in cancerPharmacology & Therapeutics, 2018
- ATR inhibition disrupts rewired homologous recombination and fork protection pathways in PARP inhibitor-resistant BRCA-deficient cancer cellsGenes & Development, 2017
- ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1ANature Communications, 2016
- ATM Mutations in Cancer: Therapeutic ImplicationsMolecular Cancer Therapeutics, 2016
- ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cellsBlood, 2016